PPARG and type 2 diabetes mellitus: Cumulatively, these results provide solid evidence for the anti-inflammatory and cardioprotective effect of PPAR-γ therapy and pioglitazone, which so far represents a valid therapeutic strategy in T2DM patients with established ASCVD ([155], http://www.siditalia.it/clinica/standard-di-cura-amd-sid).